v3.25.2
Collaborations, Licensing and Other Arrangements - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Oct. 31, 2018
Dec. 31, 2023
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
May 31, 2018
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Deferred revenue - current     $ 10,954,000   $ 10,954,000   $ 12,407,000  
Deferred revenue - non-current     45,472,000   45,472,000   51,160,000  
Total revenue from UT     76,527,000 $ 72,386,000 154,881,000 $ 138,649,000    
Milestone payments         639,000      
Amphastar                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Performance obligation transaction price         2,500,000      
Performance obligation transaction price recognized     500,000   1,000,000      
Performance obligation transaction price yet to recognize         1,000,000      
Manufacturing Services                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Total revenue from UT     900,000 1,000,000 1,200,000 1,400,000    
Collaborations and services                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Total revenue from UT     22,845,000 26,014,000 52,221,000 50,862,000    
AFREZZA product sales                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Total revenue from UT     22,454,000 20,780,000 41,427,000 39,544,000    
United Therapeutics Corporation                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Total revenue from UT     53,452,000 51,570,000 112,275,000 99,032,000    
Collaboration and License Agreement | United Therapeutics Corporation                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Deferred revenue     55,400,000   55,400,000   62,400,000  
Deferred revenue - current     10,900,000   10,900,000   12,300,000  
Deferred revenue - non-current     44,500,000   $ 44,500,000   100,000  
Royalty percentage 10.00%              
Royalty future net sales percentage   1.00%            
Royalty retaining percentage   9.00%            
License agreement description         There have been various amendments to the UT License Agreement and the CSA since inception. As amended, the term of the CSA continues until December 31, 2031 (unless earlier terminated) and is thereafter renewed automatically for additional, successive two-year terms unless (i) UT provides notice to the Company at least 24 months in advance of such renewal that UT does not wish to renew the CSA or (ii) the Company provides notice to UT at least 48 months in advance of such renewal that the Company does not wish to renew the CSA      
Collaboration and License Agreement | United Therapeutics Corporation | Facility Expansion Services                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Deferred revenue     55,300,000   $ 55,300,000      
Collaboration and License Agreement | United Therapeutics Corporation | Other Administrative Services                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Deferred revenue     61,300,000   61,300,000      
Commercial Supply Agreement | United Therapeutics Corporation | Collaborations and services                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Total revenue from UT     22,224,000 25,978,000 51,042,000 50,442,000    
Co-Promotion Agreement | Collaborations and services | Amphastar                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Total revenue from UT     500,000   1,000,000      
Supply and Distribution Agreement | AFREZZA product sales | Biomm                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Total revenue from UT         0      
License and Distribution Agreement | Cipla Ltd                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Deferred revenue     1,100,000   1,100,000   1,200,000  
Deferred revenue - current     100,000   100,000   100,000  
Deferred revenue - non-current     1,000,000   $ 1,000,000   1,100,000  
Marketing and distribution agreement date         2018-05      
Milestone payments             $ 1,100,000  
License and Distribution Agreement | Collaborations and services | Cipla Ltd                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Total revenue from UT     $ 37,000 $ 36,000 $ 73,000 $ 73,000    
License and Distribution Agreement | Nonrefundable Licensing Fee                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Deferred revenue               $ 2,200,000